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Introduction: Agitated patients in the prehospital setting pose challenges for both patient care and 
emergency medical services (EMS) provider safety. Midazolam is frequently used to control agitation in 
the emergency department setting; however, limited data exist in the prehospital setting. We describe 
our experience treating patients with midazolam for behavioral emergencies in a large urban EMS 
system. We hypothesized that using midazolam for acute agitation leads to improved clinical conditions 
without causing significant clinical deterioration. 
Methods: We performed a retrospective review of EMS patient care reports following implementation 
of a behavioral emergencies protocol in a large urban EMS system from February 2014–June 2016. 
For acute agitation, paramedics administered midazolam 1 milligram (mg) intravenous (IV), 5 mg 
intramuscular (IM), or 5 mg intranasal (IN). Results were analyzed using descriptive statistics, Levene’s 
test for assessing variance among study groups, and t-test to evaluate effectiveness based on route. 
Results: In total, midazolam was administered 294 times to 257 patients. Median age was 30 
(interquartile range 24–42) years, and 66.5% were male. Doses administered were 1 mg (7.1%) and 
5 mg (92.9%). Routes were IM (52.0%), IN (40.8%), and IV (7.1%). A second dose was administered 
to 37 patients. In the majority of administrations, midazolam improved the patient’s condition (73.5%) 
with infrequent adverse events (3.4%). There was no significant difference between the effectiveness 
of IM and IN midazolam (71.0% vs 75.4%; p = 0.24). 
Conclusion: A midazolam protocol for prehospital agitation was associated with reduced agitation 
and a low rate of adverse events. [West J Emerg Med. 2020;21(3)677–683.]
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Population Health Research Capsule
What do we already know about this issue?
While prehospital agitation poses a significant 
challenge to emergency medical services 
providers, medications can help improve safety of 
care and transport. 
What was the research question?
Is a prehospital protocol using midazolam for 
agitation safe and effective?
What was the major finding of the study?
Use of this protocol was associated with decreased 
agitation and had a low rate of complications.
How does this improve population health?
Most of the agitated patients in our study were 
from racial minorities. Identifying the optimal 
treatment for agitation is important for this at-
risk population. 
INTRODUCTION
Agitated patients pose challenges for both patient care and 
emergency medical services (EMS) provider safety, but there 
is no consensus regarding the optimal medication to manage 
prehospital agitation.1 Behavioral emergencies are complex 
with numerous etiologies, including neurologic, traumatic, 
intoxication, acute psychiatric, infectious, and metabolic.2 While 
EMS providers can use de-escalation techniques and physical 
restraints, pharmacologic intervention may be required when non-
pharmacologic methods fail to effectively control agitation.3,4
Previous studies in the emergency department (ED) setting 
demonstrate that benzodiazepines and antipsychotics can be 
effective agents todecrease  patient’s level of agitation.5–7 When 
given alone, benzodiazepines have a well-established safety 
profile, a rapid onset of action, and are effective in treating 
agitation.8,9 Specifically, midazolam provides a quicker onset 
when compared to lorazepam and haloperidol while maintaining 
equivalent sedative potency.6,10,11 Additionally, midazolam 
can be administered via the intranasal (IN) route as well as 
the intravenous (IV) and intramuscular (IM) routes.12 The 
IN route offers a needle-less option for EMS providers, thus 
decreasing the risk of blood-borne pathogen exposure.13,14 While 
IN midazolam has been proven to be safe and effective when 
administered to control seizures and for procedural sedation, there 
is limited research regarding its use for prehospital behavioral 
emergencies.15,16 Prior studies have described the IM and IV 
routes for chemical sedation, but IN administration remains 
under-studied.4,7
In this study, we report the rate of clinical improvement, need 
for repeat dosing, and rate of adverse events for a prehospital 
behavioral emergencies protocol using midazolam. Secondarily, 
we compare the effectiveness and safety of IN midazolam to IM 
midazolam for treating behavioral emergencies.
METHODS
Study Design, Population, and Setting
We performed a retrospective chart review of patients 
who were administered midazolam by EMS for behavioral 
emergencies from February 2014 through June 2016. We 
conducted this study in the Chicago EMS System, which 
serves an estimated 2.7 million residents and covers 237 square 
miles. The Chicago EMS System is a regional collaborative 
of hospital-based, EMS physicians and nurses who provide 
medical oversight for EMS provider agencies within the system, 
including the Chicago Fire Department (CFD), which provides 
emergency response to all 9-1-1 calls. CFD is an urban, fire-based 
EMS agency with over 280,000 annual transports, of which 
approximately 3% are for behavioral or psychiatric emergencies 
and related complaints.
In 2014, the Chicago EMS system implemented a new 
protocol for management of patients with behavioral emergencies 
using midazolam. Paramedics had previous training on the use 
of IN medications and on the use of IV midazolam for other 
indications. They underwent additional training for the use of 
midazolam for behavioral emergencies including IN delivery. Per 
protocol, paramedics attempted verbal de-escalation techniques 
and physical restraint, but if a patient remained combative and 
physically dangerous to themselves and others, paramedics could 
administer midazolam. Midazolam dosing was 1 milligram (mg) 
IV or 5 mg either IM or IN (repeating once as needed), guided 
by prior studies.7,10,11,20,21 EMS providers then documented the 
dose and route of midazolam administration in addition to the 
patient’s response to therapy with one of the following options: 
a) clinical deterioration; b) no change; c) slight improvement; 
or d) significant improvement. Paramedics also documented the 
indication for midazolam administration as either “behavioral 
emergency” or “seizures” in the electronic patient care report.
Using SafetyPAD software (ESO Solutions Inc, Austin, 
TX), we extracted all EMS patient care reports from February 
2014 through June 2016 of patients for whom 9-1-1 was called 
and in which midazolam was administered. We included all 
cases in which midazolam was administered to adult patients for 
behavioral emergency via the IM, IN, or IV route. We excluded 
all cases in which midazolam was given for indications other 
than behavioral emergency, cases in which midazolam was 
administered other than via IM, IN, or IV routes, and cases with 
dosages outside the range prescribed in the protocol. Per EMS 
patient care protocol, we excluded patients less than 18 years of 
age or greater than 60 years of age. Additionally, we excluded 
cases if key data elements were missing, such as dose, route, or 
patient response. 
Patient demographic information including age, gender, 
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and race was collected and included in analysis. Additionally, an 
unblinded abstractor (RH) reviewed all charts for complications, 
predefined as systolic blood pressure < 100, oxygen saturation < 
95%, use of airway intervention, and mention of provider injury. 
RH was trained in chart abstraction by another author (CTR). 
Meetings were held weekly during chart abstraction to answer 
questions and review results. 
Outcomes and Analytical Methods
We evaluated the dose, route, need for repeat dosing, and 
clinical effect of midazolam administrations, and we performed 
descriptive statistics for administrations of midazolam for 
behavioral emergencies. Levene’s test was used to assess variance 
between aggregate groups of “any improvement” (significant 
and slight improvement) and “no improvement.” Using t-tests, 
we compared effectiveness between the routes and rate of 
adverse events for IN and IM administrations. We used Stata 15 
(StataCorp, College Station, TX) to create descriptive statistics, 
calculate confidence intervals (CI), and perform the t-tests.
Human Subjects Committee Review 
Northwestern University’s institutional review board 
approved the study. 
RESULTS
During the study period, 478 patients received midazolam. 
We excluded 221 cases for indications other than behavioral 
emergency, deviations from dosing protocol, or missing data 
(Figure 1). After exclusions, we included 294 administrations to 
257 patients. Patient characteristics are reported in Table 1.
Patient Encounters with Prehospital Midazolam 
Administration for Behavioral Emergency
478 Total Patients 
with Midazolam 
Administration
257 Patient 
Encounters with 
Per Protocol 
Midazolam 
Administration
294 Verified 
Midazolam 
Administrations
Intramuscular 
Administration 
(n=138)
Intramuscular 
Administration 
(n=15)
1st Dose 
(n=257)
2nd Dose 
(n=37)
[n=14]
[n=1]
[n=1] [n=12]
Intranasal 
Administration 
(n=107)
Intranasal 
Administration 
(n=13)
221 Patient Encounters 
Excluded After Chart Review
Exclusion Criteria
Administration 
Indication other 
than Behavioral 
Emergency 
(n=41)
Incomplete or 
Missing Key 
Data Elements 
(n=8)
Off Protocol 
Dosing 
(n=172)
Intravenous 
Administration 
(n=12)
Intravenous 
Administration 
(n=9)
[n=9]
Figure 1. Patient encounters reviewed for midazolam administration in prehospital.
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Including all administrations of midazolam (n = 294), 
paramedics noted improvement in 73.5% of cases, 34.5% (95% 
CI, 29.6-39.8%) of which had substantial improvement in 
level of agitation and 39.3% (95% CI, 34.2-44.7%) had slight 
improvement. No improvement was noted in 25.5% (95% CI, 
21.1-30.5%) of cases, and 0.6% (95% CI, 0.1-2.4%) had clinical 
deterioration. Of all administrations, 52.0% were IM, 40.8% 
were IN, and 7.1% were IV. The doses administered were 1 mg 
(7.1%) and 5 mg (92.9%).
In the subset of first-dose midazolam administrations (n = 
257), paramedics reported substantial improvement in 32.7% 
(95% CI, 27.2-38.7%), slight improvement in 39.3% (95% CI, 
33.5-45.4%), no change in 27.2% (95% CI, 22.1-33.0%), and 
deterioration in 0.8% (95% CI, 0.1-3.1%) (Figure 2). The routes 
were IM (53.7%), IN (41.6%), and IV (4.7%). The majority 
of first doses were 5 mg. (Table 2). Response rates to specific 
routes are shown in Figure 2.
In those patients requiring a repeat dosage (n = 37), 
paramedics reported improvement in 83.7% of cases, with 
substantial improvement noted in 43.2% (95% CI, 28.0-59.9%) 
of patients, and slight improvement documented for 40.5% 
(95% CI, 25.7.0-57.3%) of patients. No change was noted in 
16.2% (95% CI, 7.3-32.4%) of patients (Figure 3). The routes of 
the second dose were IV (24.3%), IM (40.5%), and IN (35.1%) 
(Table 2). Of those receiving a second dose, their responses to 
the first dose were as follows: no response (75.7%, 95% CI, 
58.9-87.1%); slight improvement (18.9%, 95% CI, 9.1-35.3%); 
substantial improvement (2.7%, 95% CI, 0.4-17.9%); and 
clinical deterioration (2.7%, 95% CI, .4-17.9%).
IM and IN routes of midazolam administration were 
compared for effectiveness after applying Levene’s test 
to compare “any improvement” (“slight improvement” 
+ “substantial improvement”) to “no improvement” (“no 
improvement” + “clinical deterioration”). The datasets were 
found to be homogenous (p = 0.18). Using a t-test, we found 
no significant difference between “any improvement” after 
IN midazolam (71.0%) and IM (75.4%, p = 0.24). There was 
also no significant difference found between the documented 
adverse events of IM midazolam (3.9%) and IN (3.3%, p = .79). 
Additionally, we found no significant difference between the 
rates of reported EMS provider injury for IM (3.9%) and IN 
(1.7%, p=.27) doses. The majority of these injuries were kicks 
or bites by the patient, with no needlestick injuries reported. 
Paramedics reported six adverse events thought to be due 
to midazolam administration, and an additional three adverse 
events were identified upon chart review. Adverse events 
included hypotension (systolic blood pressure < 100 millimeters 
of mercury [mmHg]) (n = 3); hypoxia with airway intervention 
required (n = 1); hypoxia without airway intervention (n = 1); 
unresponsiveness (n = 2); traumatic cardiac arrest (n =1); and 
worsening agitation (n = 2). For the nine cases, all happened 
after a single 5 mg dose administered via IM (n = 6) or IN (n 
= 3) routes. The patient who received an airway intervention 
had an oropharyngeal airway placed and bag-valve-mask 
ventilation performed. In the two cases of hypotension with 
systolic pressures less than 100 mmHg, none of the cases had a 
systolic blood pressure less than 90 mmHg systolic. Of patients 
experiencing unresponsiveness, two were given midazolam for 
agitation after naloxone was administered for suspected opioid 
overdose. The patient who experienced traumatic cardiac arrest 
sustained blunt trauma injuries after a four-story fall. This 
patient received 5 mg of midazolam IM to facilitate safe and 
timely transport in the setting of severe trauma and experienced 
cardiac arrest during transport. 
DISCUSSION
To our knowledge, this study represents the largest cohort 
of prehospital patients administered midazolam as a single 
agent for behavioral emergency. Paramedics reported clinical 
improvement in a majority of patients following midazolam 
administration. Only 14.4% of patients required a second dose, 
after which, the majority were assessed by paramedics to have 
a clinical improvement. Over 294 administrations, adverse 
events were noted in 3.1%, all with IM or IN dosing. Based on 
Characteristic Total patients (n = 257)
Age – median years (IQR) 30 (24-42)
Male gender 171 (66.5%)
Race  
African American 138 (53.7%)
White 65 (25.3%)
Hispanic 43 (16.7%)
Asian 6 (2.3%)
Other 2 (0.8%)
Unknown 3 (1.2%)
IQR, interquartile range.
Table 1. Characteristics of patients receiving midazolam for 
behavioral emergencies.
Administration 
Characteristic
Initial Dose 
(n = 257)
Repeat Dose 
(n = 37)
Dose administerd, n (%)
1mg 12 (4.7%) 9 (24.3%)
5 mg 245 (95.3%) 28 (75.7%)
Administration route, n (%)
IM 138 (53.7%) 15 (40.5%)
IN 107 (41.6%) 13 (35.1%)
IV 12 (4.7%) 9 (24.3%)
IM, intramuscular; IN, intranasal; IV, intravenous, mg, milligrams.
Table 2. Characteristics of midazolam administrations for 
behavioral emergencies.
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Figure 2. Subjective clinical change after initial midazolam administration for behavioral emergencies as reported by paramedics.
IM, intramuscular; IN, intranasal; IV, intravenous.
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Figure 3. Subjective clinical change after repeat midazolam administration for behavioral emergencies as reported by paramedics.
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this improvement rate and low complication rate, a prehospital 
behavioral emergencies protocols using midazolam to control 
agitation may be considered for use in EMS systems.
One notable advantage of midazolam over alternative 
agents is the possibility for IN administration. In this study, 
IN administration represented 40.8% of the midazolam 
administrations, suggesting a preference of IN route by EMS 
providers. Additionally, we found IN midazolam to be no less 
effective than IM midazolam. These results suggest that IN 
administration may represent a preferable route of delivering 
midazolam, particularly as the IN route eliminates the risk of 
needlestick provider injury. 
Adverse events after midazolam use for behavioral 
emergency were rare in this study, with only 3.1% of patients 
experiencing an adverse event, all after initial administration 
of midazolam. Hypoxia and apnea were also rare, with only 
one patient requiring any airway intervention and no patients 
requiring intubation in the field. For the patient administered 
midazolam in order to facilitate transport in the setting of blunt 
trauma, they likely experienced cardiac arrest due to injuries 
rather than midazolam administration. Further studies are 
needed to investigate the safety of midazolam administration 
in the setting of known or suspected opioid use as prior studies 
have demonstrated that concurrent benzodiazepine and opioid 
administration increases the risk of respiratory depression.17–19 
Prehospital providers are frequently exposed to agitated 
patients, and improved strategies are needed to safely care 
for these patients.3,14 The optimal agent for safely managing 
agitation in the prehospital setting after de-escalation techniques 
have failed remains to be determined. Benzodiazepines are one 
of the most frequently used classes of drugs for acute agitation 
due to their safety profile and sedating effects. IM doses of 
short-acting benzodiazepines like midazolam have shown 
rapid onset of action and more rapid effect when compared 
to antipsychotics alone.6,7,10,20 However, sedating effects 
from benzodiazepines have raised concerns about potential 
respiratory depression and their use may lead to an increase in 
respiratory adverse events.6,7,20,21 
An alternate agent for prehospital agitation that has 
attracted attention over the last decade is ketamine. Despite 
being used since the 1960s, ketamine has only recently been 
evaluated for use in treating agitation in the prehospital 
and ED settings and has been shown to be effective in 
controlling agitated patients in several studies.22–24 However, 
research on the use of ketamine in the prehospital setting has 
demonstrated hypoxia, increased secretions, and laryngospasm 
requiring intubation following ketamine administration.22–25 
In one of the largest studies to date evaluating ketamine for 
prehospital agitation, ketamine performed well in comparison 
to haloperidol in controlling agitation but with an intubation 
rate of 39%.23 While further studies are needed to clarify the 
use of ketamine for prehospital agitation, alternatives such as 
benzodiazepines may be preferable given the low frequency of 
complications requiring advanced airway as shown in this and 
other studies.6,10 
LIMITATIONS
Using paramedic impression as an outcome limits the 
results of this study. While paramedic impression is certainly 
important for prehospital treatments and has been used in prior 
studies, using a standardized aggression scoring systems may 
more accurately measure effectiveness of midazolam in treating 
agitation and improve external validity.24,26 A large portion of 
patients receiving 1 mg of IV midazolam required a second 
dose. This likely represents an under-dosing by the protocol, 
and the study EMS system has subsequently implemented a 
change to 2 mg for IV doses. We did not investigate the need 
for additional sedation in the ED, and we look forward to future 
studies linking prehospital and ED data.
We did not limit midazolam administration to excited 
delirium, so these results may not accurately represent the 
effects of midazolam on excited delirium. Excited delirium 
represents a small portion of agitated patients though, and 
protocols are necessary for control of agitation in a variety of 
clinical scenarios. Additionally, despite 3% of transports being 
for behavioral complaints, less than 0.1% of patients received 
midazolam during the study period. This likely suggests that 
non-pharmacological approaches may be adequate to address 
the majority of behavioral emergencies.
Adverse events were limited to paramedic documentation 
and chart review, which may not capture all adverse events, 
particularly paramedic injuries. We excluded more than a third 
of cases for dosing deviations, the large portion of which were 
due to online medical control. Excluding these deviations might 
bias the results by missing adverse events, but on analysis of 
all midazolam administrations, the adverse rate was similar at 
2.9% for all administrations compared to 3.1% for per protocol. 
Lastly, this study was performed in a single EMS system, and 
further studies could verify effectiveness in other settings. 
CONCLUSION
In a large urban EMS system, we found that a prehospital 
behavioral emergencies protocol using midazolam was 
associated with improved agitation and a limited number of 
adverse events. Additionally, we demonstrate the effective 
use of IN midazolam for use in a prehospital behavioral 
emergencies protocol. Further studies will be needed to validate 
these findings in other EMS systems and to compare midazolam 
to other pharmacological options to help determine the ideal 
agent for the agitated prehospital patient.
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